## R-CYVE #1 – High risk (Group C) – CNS positive

**Rituximab (R)**
-	Route: IV
-	Dosage: 375 mg/m2/dose
-   Dilute in 0.9% NaCl to final concentration 1 mg/ml  
-	Used on day 0
-	Infusion guide: 
    + Initial rate: 0.5mg/kg/hr (maximum of 50 mg/hr) for the 1st hour 
    + If no hypersensitivity or infusion-related events: Increase infusion rate by 0.5 mg/kg/hr (maximum 50 mg increase per hour) every 30 minutes, to a maximum rate of 400 mg/hr. 

**Cytarabine (ARAC)**
-	Route: IV over 12 hours
-	Dosage: 50 mg/m2/dose, in 250ml NS, continuous infusion over 12 hrs from 20h to 08h on Days 1 to 5
-	Used on Days 1 to 5

**IV high dose cytarabine (Y)**
-	Route: IV over 3 hours
-	Dosage: 3000mg/m2/dose in 250ml NS over 3 hours infusion to start after continuous infusion of cytarabine above run from 08h to 11h for 4 days

**IV etoposide (VE)**
-	Route: IV over 2 hours
-	Dosage: 200 mg/m2/dose in 500ml or 1000ml NS (maximun concentration 0.4 mg/ml), run over 2 hours at 14h to 16h for 4 days

**Triple Intrathecal (TIT)**

Triple intrathecal (IT) therapy doses, according to patient age, are as follows:

-	For patients under 1 year of age, administer methotrexate 8 mg, hydrocortisone 8 mg, and cytarabine 16 mg, in a total volume of 3 mL.
-	For patients aged 1 to 2 years, administer methotrexate 10 mg, hydrocortisone 10 mg, and cytarabine 20 mg, in a total volume of 4 mL.
-	For patients aged 2 to 3 years, administer methotrexate 12 mg, hydrocortisone 12 mg, and cytarabine 24 mg, in a total volume of 5 mL.
-	For patients older than 3 years, administer methotrexate 15 mg, hydrocortisone 15 mg, and cytarabine 30 mg, in a total volume of 6 mL.
-	These doses are to be given on Day 0 for CNS positive only
-	Important note: Should be given before folinic acid is started

**G-CSF**
-	Route: subcutaneously
-	Dosage: 5 mcg/kg/day
-	Used on days 7 to 21. G-CSF should be discontinued when the post nadir ANC reaches 3000/mm3, even if prior to day 21. 
